TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25528104
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (AT) group
Study: 16187871
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg cortisol
Study: 19735771
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTX‐A) combined with a defined therapy program
Study: 19735771
Drug: Therapy alone
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy alone
Study: 19735771
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (BTX‐A and therapy alone)
Study: 18067007
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (81 mg) with thalidomide/dexamethasone
Study: 18067007
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin with thalidomide/dexamethasone
Study: 18067007
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin with lenalidomide-containing regimen (clarithromycin, lenalidomide, dexamethasone)
Study: 18067007
Drug: Dexamethasone alone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone alone (without aspirin)
Study: 15519009
Drug: Heparin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin + routine GP IIb/IIIa inhibition
Study: 19238088
Drug: Fluoxetine 60-80
Normalized name: fluoxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 60-80 mg/day
Study: 28263650
Drug: Supportive-expressive (SE)
Normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-expressive (SE) psychodynamic treatment
Study: 25212601
Drug: 3D conformal
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D conformal radiation therapy (3D‐CRT, 70 Gy/35 fractions)
Study: 25212601
Drug: Intensity‐modulated radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity‐modulated radiation therapy (IMRT, 76 Gy/38 fractions)
Study: 25212601
Drug: APC for
Normalized name: Recombinant human activated protein C (rH-APC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APC for Grade 2 or 3 rectal bleeding
Study: 12453903
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg b.i.d.)
Study: 18390799
Drug: Metformin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1 g b.i.d.)
Study: 21873632
Drug: Aspirin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (75 mg daily)
Study: 9431533
Drug: 5% acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% acyclovir cream
Study: 30672128
Drug: mirogabalin 30
Normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: mirogabalin 30 mg/day
Study: 30672128
Drug: mirogabalin 15
Normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: mirogabalin 15 mg/day
Study: 11991778
Drug: Daily Undulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Undulating Periodization (DUP)
Study: 24461313
Drug: Krill oil
Normalized name: Krill oil
DrugBank: Krill oil (DB16615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krill oil (0.5, 1, 2, or 4 g/day)
Study: 22012469
Drug: 0.8% hyaluronan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8% hyaluronan gel
Study: 11894974
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ACTH [1‐24] (0.1 microg, 0.5 microg, 1.0 microg per 1.73 m2)
Study: 11894974
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose ACTH [1‐24] (250 microg, 60-minute HDT)
Study: 11894974
Drug: 8-h infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-h infusion test (250 microg ACTH [1‐24] at a constant rate over 8 h)
Study: 11894974
Drug: Insulin hypoglycaemia
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin hypoglycaemia test (IHT)
Study: 11894974
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ACTH [1‐24] (0.1 microg, 0.5 microg, 1.0 microg)
Study: 11894974
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose ACTH [1‐24] (HDT)
Study: 9452545
Drug: Combination at-home
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination at-home and in-office system with a 15% carbamide peroxide at-home bleaching agent
Study: 24470342
Drug: Trimetazidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (20 mg three times daily)
Study: 378729
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg three times daily)
Study: 3141537
Drug: Aspirin (topical)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (topical)
Study: 3141537
Drug: Indomethacin (topical)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin (topical)
Study: 3141537
Drug: Piroxicam (topical)
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroxicam (topical)
Study: 25470086
Drug: Oral antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antipsychotic regimens
Study: 30393935
Drug: ATRA plus
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA plus chemotherapy
Study: 31455589
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive pills containing drospirenone
Study: 27986370
Drug: Ethyl chloride
Normalized name: Ethyl Chloride
DrugBank: Ethyl chloride (DB13259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethyl chloride spray
Study: 16634384
Drug: Ametop cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ametop cream
Study: 8151317
Drug: Multiagent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiagent chemotherapy and cranial irradiation
Study: 8151317
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of methotrexate and cytarabine (ara‐c)
Study: 3047215
Drug: prednisolone 21‐phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisolone 21‐phosphate 30 mg (PP)
Study: 3047215
Drug: beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beclomethasone dipropionate 1 mg (BDP)
Study: 23426902
Drug: Extended-release carbidopa-levodopa
Normalized name: carbidopa / levodopa Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release carbidopa-levodopa (IPX066)
Study: 23426902
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (IPX066 and IR CD-LD)
Study: 22101764
Drug: Dexpramipexole (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexpramipexole (50, 150 or 300 mg d(‐1))
Study: 22101764
Drug: Dexpramipexole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexpramipexole (50 mg d(‐1) or 300 mg d(‐1))
Study: 18979718
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination perindopril-indapamide
Study: 16988008
Drug: Ebola virus
Normalized name: Anti-Ebola virus IgG antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebola virus DNA vaccine (2 mg, 4 mg, or 8 mg)
Study: 8147164
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion for Bishop score > 8
Study: 25219986
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg methylprednisolone acetate injected postoperatively into the masseter muscle
Study: 22964250
Drug: LFF571 single
Approvals — FDA: no, EMA: no, PMDA: no
Description: LFF571 single doses (25 mg, 100 mg, 400 mg, and 1,000 mg)
Study: 22964250
Drug: LFF571 multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: LFF571 multiple doses (25 mg, 100 mg, or 200 mg every 6 h for 10 days)
Study: 19306963
Drug: Barusiban (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barusiban (0.3, 1, 3, or 10 mg)
Study: 19148936
Drug: No inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: No inhaled nitric oxide (no iNO)
Study: 15125004
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fuzzy merging and wall-thickening analysis
Study: 11453312
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (0.8 mg m(‐2) day(‐1) for 1 month, then 0.4 mg m(‐2) day(‐1) for 3 months)
Study: 8061853
Drug: Spirapril 6
Normalized name: spirapril 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril 6 mg/day
Study: 8061853
Drug: Spirapril 12
Normalized name: spirapril 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril 12 mg/day
Study: 8061853
Drug: Spirapril 24
Normalized name: spirapril 24 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril 24 mg/day
Study: 24006669
Drug: Acupuncture group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture group received acupuncture stimulation at various acupoints (Baihui, Neiguan, Sanyinjiao, Taichong, etc.) once daily, 5 times a week for 20 times.
Study: 21869695
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg for 2 weeks
Study: 16384626
Drug: CC haplotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC haplotype
Study: 16384626
Drug: -842 CC
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: -842 CC genotype or CC haplotype
Study: 15325930
Drug: Subclinical hyperthyroidism
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subclinical hyperthyroidism (during antithyroid therapy)
Study: 10571698
Drug: Antithyroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid treatment
Study: 15240983
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg encapsulated sumatriptan
Study: 10987048
Drug: Medico-surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medico-surgical treatment (including nerve surgical decompression)
Study: 10987048
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (steroids only)
Study: 2073120
Drug: Clotrimazole troches
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole troches (10 mg each, five troches daily for 14 days)
Study: 2073120
Drug: Fluconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (100 mg daily for 14 days)
Study: 30226796
Drug: Extended-release carbidopa-levodopa
Normalized name: carbidopa / levodopa Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release carbidopa-levodopa (CD-LD) product
Study: 30226796
Drug: Immediate-release carbidopa-levodopa
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release carbidopa-levodopa (CD-LD) product
Study: 25169642
Drug: Escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10 mg single dose)
Study: 22896670
Drug: Statin-fenofibric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin-fenofibric acid therapy (FNA)
Study: 20668372
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml black tea extract (BTE) daily for weeks 1-4 (increasing to 600 ml by week 4)
Study: 20668372
Drug: 600 ml
Normalized name: urinary bag 600 mL-10" MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 ml black tea extract (BTE) daily
Study: 20668372
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml black tea extract (BTE) daily (control group)
Study: 7587908
Drug: Multiple injection
Normalized name: sodium acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple injection regimen of insulin therapy (Group II, n = 9)
Study: 19797937
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg controlled-release oxycodone
Study: 10898540
Drug: Docetaxel 60
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 60 mg/m2 followed by CPT‐11 190 mg/m2 on day 1, repeated every 3 weeks
Study: 8438659
Drug: Twice-weekly exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly exercise
Study: 3940518
Drug: Oral meclizine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral meclizine
Study: 28468653
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin (81 mg) daily administration, initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA
Study: 28468653
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin (81 mg)
Study: 22751026
Drug: Analgesics after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics after ED care
Study: 1598953
Drug: cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cromolyn sodium 4% ophthalmic solution
Study: 4044294
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg riboflavin supplementation
Study: 4044294
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg riboflavin supplementation
Study: 4044294
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg riboflavin supplementation
Study: 4044294
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg riboflavin load
Study: 2493400
Drug: Danazol (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (800 mg per day)
Study: 2963213
Drug: Nafarelin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin (both doses) and Danazol
Study: 26951845
Drug: PEITC (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEITC (10 mg in 1 mL of olive oil, 4 times per day)
Study: 27916036
Drug: Patient Controlled
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient Controlled Intravenous Analgesia (PCIA)
Study: 15753744
Drug: Decision support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decision support on (smart infusion pumps with integrated decision support software)
Study: 15246599
Drug: 9-valent pneumococcal
Normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-valent pneumococcal conjugate vaccine
Study: 10452624
Drug: Combined vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vaccine
Study: 31314753
Drug: Weight-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based dosing for diethylcarbamazine (DEC; 6 mg/kg) and ivermectin (IVM; 200 ug/kg)
Study: 31314753
Drug: New dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: New dosing pole with a 6-tablet maximum for both DEC and IVM
Study: 20973770
Drug: Imiquimod cream
Normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod cream (5%)
Study: 30400777
Drug: Podophyllotoxin cream
Normalized name: podophyllotoxin
DrugBank: Podofilox (DB01179)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Podophyllotoxin cream (0.15%)
Study: 19958541
Drug: Verum acupuncture
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum acupuncture (treatment group)
Study: 20394651
Drug: Azacitidine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azacitidine (75 mg/m2/day SC for 7 days every 28 days)
Study: 20394651
Drug: Conventional care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional care regimens (CCR) including low-dose ara-C, BSC, or intensive chemotherapy
Study: 18759641
Drug: Risperidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (mean dose = 3.4 mg)
Study: 18759641
Drug: Olanzapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (mean dose = 14.0 mg)
Study: 18759641
Drug: Quetiapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (mean dose = 611 mg)
Study: 8941061
Drug: Four-pellet system
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-pellet system containing 174 mg NET
Study: 8941061
Drug: Five-pellet system
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-pellet system containing 266.5 mg NET
Study: 29703470
Drug: Apixaban 2.5
Normalized name: apixaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 2.5 mg BID
Study: 12779109
Drug: Ketamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (10 mg/kg) + Promethazine (1.1 mg/kg)
Study: 12779109
Drug: Ketamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (10 mg/kg)
Study: 7502276
Drug: Ketorolac infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac infusion
Study: 8010474
Drug: Ketorolac infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac infusion and bolus
Study: 28316664
Drug: Neurofeedback therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurofeedback therapy (20 sessions of 40 minutes each, 3 sessions per week)
Study: 10778884
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg DHEA administered orally at 0700 hours
Study: 8793448
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nedocromil sodium
Study: 1333423
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day itraconazole for 15 days
Study: 1333423
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day griseofulvin for 15 days
Study: 30991399
Drug: OZOILE cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: OZOILE cream (ozonides with vitamin E acetate)
Study: 30991399
Drug: 0.1% mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% mometasone furoate (topical corticosteroid)
Study: 22531061
Drug: Focused-image ultrasonography
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Focused-image ultrasonography with more treatment lines and higher joule energy at dual depths
Study: 18600434
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g PEG 400
Study: 18600434
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g PEG 400
Study: 18600434
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g PEG 400
Study: 18600434
Drug: 1.25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 g PEG 400
Study: 10930561
Drug: Caffeine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (100 mg)
Study: 9864074
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg daily for up to 12 weeks (short-term therapy)
Study: 9864074
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 52 weeks (long-term therapy)
Study: 9864074
Drug: Fluoxetine for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine for 52 weeks (long-term therapy)
Study: 2094589
Drug: Peptide Plasmodium
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide Plasmodium falciparum sporozoite vaccine conjugated to tetanus toxoid ((NANP)3‐TT) plus placebo (group 1)
Study: 10917405
Drug: Codeine 120
Normalized name: TY-PAP with Codeine 120mg-12mg/5ml Elixir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine 120 mg
Study: 788993
Drug: Codeine 60
Normalized name: codeine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine 60 mg
Study: 19753607
Drug: Trichosanthes kirilowii
Normalized name: TRICHOSANTHES KIRILOWII ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trichosanthes kirilowii (TK) seed kernels containing 3 g of punicic acid (PA) per day for 28 days
Study: 12207145
Drug: Flupenthixol 5-15
Normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupenthixol 5-15 mg/day
Study: 11148810
Drug: Timolol treatment
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol treatment
Study: 2547409
Drug: Metered-dose inhaler
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered-dose inhaler (MDI)
Study: 3826899
Drug: Metered-dose inhaler
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered-dose inhaler with holding chamber (MDI-HC)
Study: 24468407
Drug: Prismatic adaptation
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prismatic adaptation (PA) with a leftward aftereffect administered outside the scanner.
Study: 21911045
Drug: Fufangkushen colon-coated
Normalized name: Sus scrofa colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fufangkushen colon-coated capsule (FCC)
Study: 21911045
Drug: Huidi (HD,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huidi (HD, mesalazine enteric-coated tablets)
Study: 19819724
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) 800 mg oral daily for 20 weeks
Study: 16289802
Drug: Hypnotic suggestions
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic suggestions inducing negative emotions
Study: 10973133
Drug: S. melongena
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. melongena infusion (N = 19)
Study: 10973133
Drug: S. melongena
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. melongena infusion without dietary orientation (N = 38)